To determine MRI predictors for cognitive outcome in patients with early relapsingremitting multiple sclerosis (MS).
Cognitive impairment is an important feature of multiple sclerosis (MS) and may affect everyday activities. Deficits in memory, information processing speed (IPS), attention, working memory, and executive functions are frequently seen. 1 Cognitive dysfunction has long been considered to be confined to patients at later stages of the disease but such impairments have been described in clinically isolated syndromes (CIS) 2 and in early relapsing-remitting MS (RRMS). 3 The association between cognitive deficiencies and several MRI markers, including lesion load (LL), diffuse brain abnormalities, and brain atrophy, has been investigated. 1 However, little is known about the value of these parameters at the early stages of MS to predict cognitive decline over time and the value of magnetization transfer (MT) imaging parameters. We designed a longitudinal study in newly diagnosed patients with clinically definite MS (CDMS) to investigate MRI markers predictive for deteriorating cognitive function. Cross-sectional data at baseline showed that cognitive impairment was associated with magnetic resonance (MR) parameters evaluating diffuse brain damage. 3 We hypothesized that diffuse brain damage outside lesions in early RRMS detected at baseline and their change over 2 years predict the deterioration of cognitive performance over 7 years. Baseline values of various MR parameters, including LL, MT ratio (MTR) metrics, and global and central atrophy, and their change over 2 years, were investigated for predicting the deterioration of cognitive performance over 7 years.
METHODS Patients and controls. Fifty-eight patients, diagnosed with RRMS within the previous 6 months without other selection criteria, were included by the coordinating center between November 2000 and November 2001. Patients were consecutively referred by practicing neurologists from a neurologic network in southwestern France for the purpose of that study. None of these patients received disease-modifying therapies before the second exacerbation.
One patient was excluded from the study due to reconsideration of the MS diagnosis. Forty-four patients (77.2%) completed all evaluations during the 7-year study period and were used for the analysis. All patients underwent clinical and cognitive assessment at baseline (year 0) and after years 1, 2, 5, and 7, and underwent brain MRI at year 0 and year 2. A sample of 56 healthy subjects matched for sex, age, and educational level was also studied at baseline. Baseline clinical, imaging, and cognitive characteristics of patients and controls have been published previously. 3 Standard protocol approvals and patient consents. The study was approved by the institutional review board (CPP Bordeaux 2000/28) and patients gave written informed consent.
Clinical evaluation. Clinical evaluation included Expanded
Disability Status Scale (EDSS), Multiple Sclerosis Functional Composite (MSFC), and Montgomery-Åsberg Depression Rating Scale (MADRS).
Neuropsychological assessment. The neuropsychological assessment was previously described in detail. 3 It included the similarities test and the Brief Repeatable Battery (BRB-N) with the Selective Reminding Test (SRT, and 3 subscores: SRT-LTS ϭ long-term storage; SRT-CLTR ϭ consistent long-term retrieval; SRT-DR ϭ delayed recall; verbal memory), the 10/36 Spatial Recall Test (SPART) testing short-term and long-term visuospatial memory, the Symbol Digit Modalities Test (SDMT, attention and IPS), the Paced Auditory Serial Addition Test (PASAT) 3-and 2-second versions (PASAT 3s and PASAT 2s; working memory and IPS), and the Word List Generation test (WLG; verbal fluency). At year 7, we applied alternate forms for all these neuropsychological tests to limit practice effect. Data concerning other tests used at baseline (Go/No-Go; Stroop, similarities, Boston, and Ruff Figural Fluency tests) and for all tests at year 1, 2, and 5 follow-up were not used in this report, because no alternate forms were used.
At baseline, patients were classified as patient cognitively impaired (PCI) if they performed less than the 5th percentile of matched controls on at least 2 tests of the battery (n ϭ 22) and patient cognitively unimpaired (PCU) if they did not (n ϭ 22).
At each time point, the raw scores of each cognitive score were transformed to z scores using the mean and SD baseline scores of the 44 patients as the reference data. z Scores were used to study longitudinal changes of cognitive tests and correlations. Additionally, 2 domain-specific z scores were created for memory (SRT-LTS, SRT-CLTR, SRT-DR, SPART, and SPARTdelayed recall) and IPS (SDMT, PASAT 3s, and PASAT 2s). For all sequences, 26 contiguous interleaved axial slices were acquired with 5-mm slices, 256 ϫ 256 matrices, and 230 ϫ 230 fields of view. The slices were positioned to run parallel to a line joining the most inferoanterior and inferoposterior parts of the corpus callosum.
Native and preprocessed data were displayed on workstations running software developed by Bio-Clinica, Inc. (Lyon, France). The following parameters were considered in the analysis: LL, brain parenchymal fraction (BPF), which is defined as the ratio of whole brain parenchyma volume to the intracranial volume, 4 ventricular fraction (VF), defined as the ratio of ventricular volume to the intracranial volume, 5 and means of lesion and normal-appearing brain tissue (NABT) MTR masks.
Statistical analysis. Statview version 5.0 (Windows) was used for statistical analysis. Matching between patients with MS (n ϭ 44) and healthy controls (n ϭ 56) was verified using the 2 test for gender and the t test for age and years of education. For each score, the percentages of patients deteriorating or improving more than 1.0 SD of controls' scores or stable over 7 years were calculated in whole group, PCI and PCU groups. For IPS and memory domains, patients were classified in the deterioration group if they have more than 1 SD decrease based on baseline scores of healthy controls. Additionally, at the follow-up evaluations, the patients were considered cognitively deteriorated according to their deterioration score modified from Kujala et al. 6 For each domain (IPS, memory), if the subject scored below Ϫ1.0 SD compared with the norms, he or she received one deterioration point; if below Ϫ1.5 SD, 2; if below Ϫ2.0 SD, 3.
All comparisons were performed using the t test when distribution of values was normal or by nonparametric Wilcoxon test when it was not.
Participants who fulfilled all follow-ups were compared to the original sample with regard to demographic data (age, gender, and years of education), baseline neuropsychological scores, EDSS, MSFC, MADRS, disease duration, LL, MTR means, BPF, and VF.
Differences were considered significant, for all analyses, when p values were less than 5%.
Correlations between change in cognitive scores and MADRS scores were studied by Pearson correlation coefficient.
Univariate linear regressions were performed to assess correlation between individual baseline MR variables or changes over the first 2 years (LL, mean lesion MTR, BPF, VF, and mean NABT MTR) and changes over 7 years of the domain-specific cognitive z scores (memory and IPS) in the whole group. To determine which MRI parameters were the best predictors of cognitive change over 7 years in the whole group, we performed 2 stepwise multiple linear regression models for each cognitive change over 7 years (memory and IPS domains) as dependent variable. Independent variables were baseline MRI parameters (LL, mean lesion MTR, BPF, VF, and mean NABT MTR) in the 2 first models and MRI parameter changes over 2 years (LL, mean lesion MTR, BPF, VF, and mean NABT MTR) in the other models. In all models, we entered age, education level, gender, and MADRS scores as independent variables and baseline EDSS was forced in all models as a covariate. Only independent variables with a conservative significance level of p Ͻ 0.25 at the univariate analysis were entered simultaneously in the lin-ear regression model. All parameters with p Ͼ 0.05 were removed from the model by stepwise elimination.
Logistic regression analyses were also performed ( Table 1 summarizes demographic and disease characteristics of patients and controls at baseline. Patients with MS were matched to healthy controls according to gender ( p ϭ 0.16, 2 ϭ 1.98), age ( p ϭ 0.67, t ϭ 0.42), and mean number of years of education ( p ϭ 0.72, t ϭ Ϫ0.36). No statistical difference was observed for baseline demographics, clinical and cognitive scores, and MRI parameters between the 44 patients who completed all follow-ups over 7 years and the entire original cohort of 56 patients (all p values Ͼ0.05).
The percentage of patients receiving diseasemodifying therapies at any time during the study was 95.6%. During the follow-up period, 9 of the 44 patients followed over 7 years converted from RRMS to secondary progressive MS.
None of the patients reached the MADRS threshold for severe depression (MADRS Ͼ34) 7 Cognitive evolution during follow-up. The baseline results have been published. 3 Differences were observed between patients with RRMS and matched controls for memory, attention, IPS, inhibition, and conceptualization.
Nineteen out of 44 patients (43.18%) had a global deterioration score Ͼ2 (sum of memory and IPS domains deterioration scores) and 9/44 (20.45%) a score Ͼ4. The proportions of patients deteriorating by cognitive domains more than 1.0 SD of controls' scores, improving more than 1.0 SD of controls' scores and stable over 7 years, are presented in table 3 for the 3 groups (all patients, PCI, and PCU) without any difference (Fisher test) between the PCI and PCU groups, for memory ( p ϭ 0.37, odds ratio [OR] ϭ 2.05; 95% confidence interval [CI] ϭ 0.57-8.2) and IPS ( p ϭ 1.0, OR ϭ 1.0, 95% CI ϭ 0.19 -5.2). The proportion of patients deteriorating was 50% for memory (9 patients deteriorated for one score, 8 patients for 2 scores, and 5 patients for more than 2 scores), 22.7% for IPS (5 for one score and 5 for at least 2 scores), and 13.6% for WLG at year 7.
Changes over 7 years in cognitive scores were not correlated with baseline MADRS scores or MADRS change over 7 years (whole, PCI, and PCU groups) (Pearson correlation coefficient ͉r͉ Ͻ0.30, p Ͼ0.05).
Regression analyses. For memory or IPS z score change over 7 years as dependent variable, 2 multiple regression models were performed with 1) baseline MRI parameters (LL, mean lesion MTR, BPF, VF, and mean NABT MTR) as independent variables and 2) MRI changes over 2 years (LL, mean lesion MTR, BPF, VF, and mean NABT MTR). In univariate linear regression analyses, memory z score change over 7 years was associated with baseline LL and mean NABT MTR and with VF changes over 2 years. IPS z score change over 7 years was correlated with baseline MRI parameters (LL, BPF, VF, and mean NABT MTR) and with VF and BPF changes over 2 years (all p values Ͻ0.05, table 4). Parameters with p Ͻ 0.25 in univariate analyses and the baseline EDSS were entered in the 2 multivariate models (table 4) . After stepwise elimination, the only independent predictor of memory decline was the baseline NABT MTR. After stepwise elimination, baseline NABT MTR and BPF and 2 years change of VF remained in the models for prediction of IPS decline.
No MR parameter predicted WLG z score change in multivariate analysis. DISCUSSION This study emphasizes the frequency of cognitive deterioration in the early stages of MS. This deterioration, which may have many impacts in the daily life of patients, including working and social activities, needs to be detected in order to adapt therapeutic strategies. The present study was designed to determine which MR parameter, measured early in MS course, could help predict subjects who will deteriorate. The results showed that MRI parameters reflecting diffuse brain damage (BPF, VF, and mean NABT MTR) predict more strongly cognitive deterioration than lesions.
The mechanisms of cognitive dysfunction in MS are not fully understood, but convergent evidence suggests that disconnection between cortical areas might be the basis of this dysfunction. 8 Although focal lesions might contribute to this disconnection, several cross-sectional studies using diffusion and MT imaging suggested that axonal damage largely contributes to cognitive alterations by interrupting critical networks. 3, [9] [10] [11] [12] [13] [14] [15] In the present longitudinal study in early MS, we observed that baseline NABT MTR, which reflects diffuse brain injury accumulated so far, but no MR parameters studying focal lesions, predicts cognitive changes over 7 years in the 2 main domains memory and IPS, in multivariate analyses. Although LL was associated with cognitive outcome in univariate analyses, it did not remain in multivariate models. These results confirmed the importance of diffuse brain damage in cognition altera-tion in RRMS. Such disconnections could interfere with the allocation of brain resources for a specific task and may explain that the most common cognitive impairment in MS concerned IPS. 16 Recent reports have shown correlations between cognitive disabilities and central atrophy and are in agreement with the hypothesis that disconnection between the subcortical and cortical structures involved in these networks may contribute to cognitive dysfunction. [17] [18] [19] [20] [21] [22] [23] Although atrophy measures did not correlate with cognitive functions at baseline, 3 baseline BPF, a measure of global atrophy, and 2-year VF change, a measure of central brain atrophy, predict decline in IPS performance over 7 years. Although periventricular white matter atrophy could contribute to VF change, and in particular corpus callosum atrophy, which has been implicated in cognitive impairment in MS, 24 it is likely that damage of the deep gray matter and the surrounding white matter is determinant in cognitive deterioration affecting IPS in early RRMS. These results are in agreement with a recent study that analyzed the rates of atrophy in different parts of the brain and correlated them to various clinical indexes including the PASAT as part of the MSFC. 25 The authors found that a worse performance on the PASAT at follow-up was predominantly related to atrophy development around the ventricles and, to a lesser extent, brainstem atrophy.
Several studies investigated the association between MR parameters and cognition evolution in RRMS but none used MT imaging. One study showed that 1-year global atrophy rate was associated with cognitive deficiencies measured several years later. 26 In that study, prediction of cognitive deterioration could not be evaluated since cognitive data were only measured at the last follow-up. Another study that examined the relation between changes of LL and brain parenchymal volumes over 2 years together with change in cognition during the same time frame found that the best predictor was brain parenchymal volumes. 27 These 2 studies did not specifically evaluate central atrophy. Another study found that only neocortical volume changes, but not deep gray matter volume changes, were significantly associated with deteriorating cognitive performance over 2.5 years. 28 It is possible that atrophy of the cerebral cortex accounts for more of the cognitive deterioration when the disease progresses, since the mean disease duration was longer in that later study than in ours (4.0 Ϯ 2.8 vs 2.0 Ϯ 2.2 years). It has been suggested that deep central atrophy may peak at earlier stages compared to whole brain atrophy 29 and that central atrophy progresses preferentially in the early stages of the disease. 30 These data can explain that, although baseline BPF, which reflects brain whole atrophy developed so far, is predictive of cognitive deterioration, it is only the central atrophy change which accounts for cognitive deterioration in attention/IPS domain. We hypothesized that disruption of deep central brain cognitive networks involved in attention occurs in our population. It is worth mentioning that cortical atrophy also occurs in early MS 31, 32 but appears to progress less rapidly than central atrophy. 29 In our study, we did not specifically study neocortical volume. Interestingly, it was recently shown that memory performance and mesial temporal volumes, in particular hippocampal atrophy, were correlated in MS. 33, 34 This suggests regional specificity of correlations between atrophy and alterations of a given cognitive domain. In our study, we did not find correlation between memory change and atrophy measures although a trend was observed with VF change (data not shown). However, baseline NABT MTR predicted memory changes over 7 years, suggesting that diffuse alterations contribute also to the memory deficits by interrupting the relevant networks.
There are some limitations to this study. When performing imaging, it would have been informative to study regional changes in brain volume and MTR, for example, using voxel-based morphometry. Unfortunately those techniques were not available at the beginning of this study. Concerning cognition, the main limitation of longitudinal studies in MS is that relatively few patients deteriorate for cognitive scores and that a relatively large number of them remain stable. One possible reason is practice effect. To limit practice effect, we used alternate forms at the 7-year evaluation, never used in the previous evaluations, but we cannot exclude that some practice effect remains. Another explanation for the limited changes in cognitive performances is that cognitive skills deteriorate slowly at the early stages of MS because of the presence of compensatory mechanisms. 35 Further studies are needed to determine which therapeutics strategies could limit diffuse brain damage at the early stage of MS and therefore ongoing cognitive deterioration.
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